Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2001;3(1):18-26.
doi: 10.1186/ar136. Epub 2000 Nov 10.

Anti-cytokine therapy in chronic destructive arthritis

Affiliations
Review

Anti-cytokine therapy in chronic destructive arthritis

W B van den Berg. Arthritis Res. 2001.

Abstract

Tumor necrosis factor (TNF) and interleukin-1 (IL-1) are considered to be master cytokines in chronic, destructive arthritis. Therapeutic approaches in rheumatoid arthritis (RA) patients have so far focused mainly on TNF, which is a major inflammatory mediator in RA and a potent inducer of IL-1; anti-TNF therapy shows great efficacy in RA patients. However, it is not effective in all patients, nor does it fully control the arthritic process in affected joints of good responders. Directed therapy for IL-1, with IL-1 receptor antagonist, mainly reduces erosions and is marginally anti-inflammatory. It is as yet unclear whether the limited effect is akin to the RA process or linked to suboptimal blocking of IL-1. Analysis of cytokine patterns in early synovial biopsies of RA patients reveals a marked heterogeneity, with variable staining of TNF and IL-1 beta, indicative of TNF-independent IL-1 production in at least some patients. Evidence for this pathway emerged from experimental arthritises in rodents, and is summarized in this review. If elements of the models apply to the arthritic process in RA patients, it is necessary to block IL-1 beta in addition to TNF.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Simplified view of potential pathways of TNF overproduction. Deranged synoviocyte-mediated TNF production might initiate a TNF–IL-1 cascade. Note that general triggering of T cells or macrophages, as studied in arthritis models, gives rise to both TNF and IL-1, with considerable TNF-independent IL-1 production, and skewing to IL-1 when immune complexes are used as the stimulus.
Figure 2
Figure 2
Amplifying elements in erosive processes. Immune complexes (IC's) generate high levels of IL-1 and, through Fc interaction, also provide additional mediators to activate pro-metalloproteinases (MMPs). T cells might be involved in enhanced bone erosion through TNF, IL-17 and the direct production of osteoprotegerin ligand (OPG-L). T cells come close to the bone at erosion sites. IL-17 also promotes cartilage erosion; a role for OPG-L in this remains to be determined. Fc Rec, Fc receptor; LT, lymphotoxin; PMN, polymorphonuclear cell.

Comment in

Similar articles

Cited by

References

    1. Van de Loo AAJ, van den Berg WB. Effects of murine recombinant IL-1 on synovial joints in mice: measurement of patellar cartilage metabolism and joint inflammation. Ann Rheum Dis. 1990;49:238–245. - PMC - PubMed
    1. Henderson B, Pettipher ER. Arthritogenic actions of recombinant IL-1 and TNF in the rabbit: evidence for synergistic interactions between cytokines in vivo. Clin Exp Immunol. 1989;75:306–310. - PMC - PubMed
    1. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G. Transgenic mice expressing human tumor necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991;13:4025–4031. - PMC - PubMed
    1. Ghivazzani SC, Kang R, Georgescu HI, Lechman ER, Jaffurs D, Engle JM, Watkins SC, Tindal MH, Suchanek MK, McKenzie LR, Evans CH, Robbins PD. Constitutive intraarticular expression of human IL-1β following gene transfer to rabbit synovium produces all major pathologies of human RA. J Immunol. 1997;159:3604–3612. - PubMed
    1. Probert L, Plows D, Kontogeorgos G, Kollias G. The type I IL-1 receptor acts in series with TNF1 to induce arthritis in TNF1 transgenic mice. Eur J Immunol. 1995;25:1794–1797. - PubMed

MeSH terms